Modulation of Visually Evoked Potentials by an Antidepressant

This study has been completed.
Information provided by:
University Hospital Freiburg Identifier:
First received: December 6, 2005
Last updated: June 1, 2007
Last verified: May 2007
12 normal healthy controls will be treated with 50 mg sertraline once daily for three weeks. Early amplitudes of visually evoked potentials will be examined at day 0, 10 and 21 and statistically compared. This study aims to examine a putative modulation of synaptic transmission and plasticity by an antidepressant and is part of a series of studies in healthy individuals and depressed patients.

Condition Intervention
Drug: Sertraline

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Modulation of Visually Evoked Potentials by an Antidepressant

Resource links provided by NLM:

Further study details as provided by University Hospital Freiburg:

Primary Outcome Measures:
  • Amplitudes and latencies of early visually evoked potentials.

Estimated Enrollment: 12
Study Start Date: December 2005
Estimated Study Completion Date: January 2006

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy individuals 18-65 years

Exclusion Criteria:

  • history of affective oder other psyhiatric disorder
  • severe medical condition
  • pregnancy or ineffective contraception
  • active illicit drug use
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00263133

Dept. of Psychiatry, University of Freiburg
Freiburg, Germany, 79104
Sponsors and Collaborators
University Hospital Freiburg
Principal Investigator: Claus Normann, MD Dept. of Psychiatry, University of Freiburg
  More Information Identifier: NCT00263133     History of Changes
Other Study ID Numbers: VEP-1  EudraCT 2005-005417-37 
Study First Received: December 6, 2005
Last Updated: June 1, 2007
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by University Hospital Freiburg:
synaptic plasticity
visually evoked potentials

Additional relevant MeSH terms:
Antidepressive Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors processed this record on May 25, 2016